P/Q type calcium-channel antibodies in paraneoplastic cerebellar degeneration with lung cancer
Abstract
Raised levels of P/Q type voltage-gated calcium-channel (VGCC) antibodies were found in 16 (41%) of 39 patients with paraneoplastic cerebellar degeneration (PCD) and Hu antibodies were found in nine (23%). Seven of the 16 VGCC antibody-positive patients had Lambert–Eaton myasthenic syndrome (LEMS). Seven of 15 CSF samples had VGCC antibodies, with evidence of intrathecal synthesis in four. VGCC antibodies should be looked for in PCD, even if there are no symptoms of LEMS, and may be related to the cerebellar dysfunction.
Get full access to this article
View all available purchase options and get full access to this article.
References
1.
Dalmau J, Gultekin HS, Posner JB. Paraneoplastic neurologic syndromes: pathogenesis and physiopathology. Brain Pathol . 1999; 9: 275–284.
2.
Mason WP, Graus F, Lang B, et al. Small-cell lung cancer, paraneoplastic cerebellar degeneration and the Lambert–Eaton myasthenic syndrome. Brain . 1997; 120: 1279–1300.
3.
Voltz RA, Carpentier AF, Rosenfeld MR, Posner JB, Dalmau J. P/Q type voltage-gated calcium channel antibodies in paraneoplastic disorders of the central nervous system. Muscle Nerve . 1999; 22: 119–122.
4.
Hillman D, Chen S, Aung TT, Cherksey B, Sugimori M, Llinás RR. Localization of P-type calcium channels in the central nervous system. Proc Natl Acad Sci USA . 1991; 88: 7076–7080.
5.
Graus F, Dalmau J, Vallderiola F, et al. Immunological characterization of a neural antibody (anti-Tr) associated with paraneoplastic cerebellar degeneration and Hodgkin’s disease. J Neuroimmunol . 1997; 74: 55–61.
6.
Motomura M, Johnston I, Lang B, Vincent A, Newsom-Davis J. An improved diagnostic assay for Lambert–Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry . 1995; 58: 85–87.
7.
Lennon VA, Kryzer TJ, Griesmann GE, et al. Calcium-channel antibodies in the Lambert–Eaton syndrome and other paraneoplastic syndromes. N Engl J Med . 1995; 332: 1467–1474.
8.
Lang B, Newsom-Davis J. Immunopathology of the Lambert–Eaton myasthenic syndrome. Springer Semin Immunopathol . 1995; 17: 3–15.
9.
Pinto A, Gillard S, Moss F, et al. Human autoantibodies specific for the alpha1A calcium channel subunit reduce both P-type and Q-type calcium currents in cerebellar neurons. Proc Natl Acad Sci USA . 1998; 95: 8328–8333.
10.
Blumenfeld AM, Recht LD, Chad DA, DeGiorlami U, Griffin T, Jeackle KA. Coexistence of Lambert–Eaton myasthenic syndrome and subacute cerebellar degeneration: differential effects of treatment. Neurology . 1991; 41: 1682–1685.
Information & Authors
Information
Published In
Copyright
© 2002.
Publication History
Received: February 20, 2002
Accepted: May 3, 2002
Published online: September 10, 2002
Published in print: September 10, 2002
Authors
Metrics & Citations
Metrics
Citation information is sourced from Crossref Cited-by service.
Citations
Download Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.
Cited By
- Autoantibodies in neuromuscular disorders: a review of their utility in clinical practice, Frontiers in Neurology, 15, (2024).https://doi.org/10.3389/fneur.2024.1495205
- Comprehensive Analysis of Paraneoplastic Neurologic Syndrome and PNS-CARE Diagnostic Criteria in Clinical Practice, Neurology Neuroimmunology & Neuroinflammation, 11, 6, (2024)./doi/10.1212/NXI.0000000000200316
- Initial screening for neuronal autoantibodies and their putative impact on survival in patients with small‐cell lung cancer, Thoracic Cancer, 15, 17, (1350-1356), (2024).https://doi.org/10.1111/1759-7714.15318
- 40 years of autoantibody research in paraneoplastic neurological syndromes, Revue Neurologique, 180, 9, (848-861), (2024).https://doi.org/10.1016/j.neurol.2024.07.003
- Paraneoplastic neurological syndromes, The Rose and Mackay Textbook of Autoimmune Diseases, (1549-1569), (2024).https://doi.org/10.1016/B978-0-443-23947-2.00060-6
- Autoantibody-mediated central nervous system channelopathies, Neurologic Channelopathies, (235-269), (2024).https://doi.org/10.1016/B978-0-323-90820-7.00005-7
- Paraneoplastic cerebellar and brainstem disorders, Paraneoplastic Neurologic Disorders, (173-191), (2024).https://doi.org/10.1016/B978-0-12-823912-4.00030-X
- Paraneoplastic antibodies targeting intracellular antigens, Paraneoplastic Neurologic Disorders, (335-346), (2024).https://doi.org/10.1016/B978-0-12-823912-4.00021-9
- Evolution of methods to detect paraneoplastic antibodies, Paraneoplastic Neurologic Disorders, (113-130), (2024).https://doi.org/10.1016/B978-0-12-823912-4.00010-4
- Antibodies to neural cell surface and synaptic proteins in paraneoplastic neurologic syndromes, Paraneoplastic Neurologic Disorders, (347-364), (2024).https://doi.org/10.1016/B978-0-12-823912-4.00006-2
- See more
Loading...
View Options
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Personal login Institutional LoginPurchase Options
The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.
If you need immediate support or to place an order, please call or email customer service:
- 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
- 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
- [email protected]
We appreciate your patience during this time and apologize for any inconvenience.